Positron emission tomography imaging in multiple sclerosis–current status and future applications

@article{Kiferle2011PositronET,
  title={Positron emission tomography imaging in multiple sclerosis–current status and future applications},
  author={Lorenzo Kiferle and Marios Politis and Paolo A. Muraro and Paola Piccini},
  journal={European Journal of Neurology},
  year={2011},
  volume={18}
}
Background:  Multiple Sclerosis (MS) is traditionally considered as a central nervous system (CNS) white matter inflammatory disease. However, recent studies have focused on the neurodegenerative aspects of the disease, which occur early in the pathological process, providing an opportunity for therapeutic intervention and application of neuroprotective strategies. The relationship between neural inflammation and cell death remains controversial. The recent development of new radiolabelled… 
EVALUATION OF NOVEL RADIOPHARMACEUTICALS FOR POSITRON EMISSION TOMOGRAPHY IMAGING OF ANIMAL MODELS OF MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is the most common autoimmune disease of central nervous system (CNS) that causes chronic neurological impairment and clinical disability. Neuroinflammation is a major element
Positron emission tomography imaging in neurological disorders
TLDR
This review aims to explain the PET imaging technique and its applications in neurological disorders such as Parkinson’s disease, Huntington's disease, multiple sclerosis, and dementias.
Precision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive Astrocytes
TLDR
PET is a precise non-invasive imaging method for biochemical functions and has potential to enhance early and accurate diagnosis for precision therapy of MS and present the most potent targets for new biomarkers with the main focus on experimental MS research.
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers
TLDR
While several preclinical and fewer clinical studies have shown results, full-scale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives.
Recent imaging advances in neurology
TLDR
The aim of this article is to review the most recent advances in neuroimaging research in common neurological disorders such as movement disorders, dementia, epilepsy, traumatic brain injury and multiple sclerosis, and to evaluate their contribution in the diagnosis and management of patients.
Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy
TLDR
Alternative magnetic resonance contrast agents, positron emission tomographic tracers and imaging techniques could be more sensitive than Gd to early blood brain barrier alteration, and they could assess the inflammatory cell recruitment and/or the associated edema accumulation to provide a more complete picture of MS.
PET in Multiple Sclerosis
TLDR
PET in MS could be used for the investigation of underlying pathophysiology of neuroinflammation, neuronal dysfunction, and demyelination, and remyelinated, and Quantitative measures of molecular targets with PET could also have future uses in clinical trials of drug development.
Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques
TLDR
An algorithm of obtaining a contrast-enhanced brain MRI 6 months after starting a disease-modifying therapy, and considering a gadolinium-enhancing lesion on that scan to indicate suboptimal response to therapy is proposed.
Surrogate Markers in Multiple Sclerosis: The Role of Magnetic Resonance Imaging
TLDR
MRI has been included in the diagnostic work-up of patients with clinically isolated syndromes suggestive of MS and the utility of advanced MRI techniques in clinical trial monitoring and in assessing individual patients’ response to treatment still needs to be assessed.
Neuroradiological aspects of Multiple Sclerosis : from early signs to late disease stages
TLDR
Nuroradiological aspects of MS are described, from its earliest signs to late stages, by describing the frequency and significance of incidental MRI findings suggestive of MS, and by studying corpus callosum atrophy as a biomarker for cognitive and physical disability in MS over a wide range of disease duration.
...
1
2
3
4
...

References

SHOWING 1-10 OF 53 REFERENCES
PET visualization of microglia in multiple sclerosis patients using [11C]PK11195
TLDR
[11C]PK11195 and PET are able to demonstrate inflammatory processes with microglial involvement in MS, and an increase of normal‐appearing white matter (NAWM) uptake was found, propagating NAWM as the possible real burden of disease.
Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers
TLDR
The new PBR ligands proposed as challengers of [11C]PK11195 are reviewed, critically analyze preclinical imaging studies and discuss their potential as neuroinflammation imaging agents.
Imaging of multiple sclerosis: Role in neurotherapeutics
TLDR
The role of conventional and advanced imaging techniques with an emphasis on neurotherapeutics is reviewed, including magnetization transfer, fluid attenuated inversion recovery, diffusion, magnetic resonance spectroscopy, functional MRI, and nuclear imaging techniques, which add to the understanding of the pathogenesis of MS.
In Vivo Quantification of Myelin Changes in the Vertebrate Nervous System
TLDR
These studies indicate that, for the first time, [11C]CIC–PET can be used as an imaging marker of myelination, which has the potential to be translated into clinical studies in multiple sclerosis and other myelin-related diseases for early diagnosis, subtyping, and efficacy evaluation of therapeutic treatments aimed at myelin repair.
The relationship between MRI and PET changes and cognitive disturbances in MS
Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: Preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients
TLDR
The present findings support the working hypothesis that [(11)C]vinpocetine is a potentially useful PET marker of regional and global brain damage resulting in glia accumulation locally or globally in the human brain.
Multiple sclerosis: an immune or neurodegenerative disorder?
TLDR
Data that support neurodegeneration as the major cause of irreversible neurological disability in MS patients are reviewed and it is questioned whether inflammatory demyelination is primary or secondary in the disease process.
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.
This study identifies by microautoradiography activated microglia/macrophages as the main cell type expressing the peripheral benzodiazepine binding site (PBBS) at sites of active CNS pathology.
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
TLDR
Clinical and pathological findings in 12 patients with relapsing and remitting multiple sclerosis, who died during or shortly after the onset of a relapse, raise the possibility of some novel process underlying new lesion formation in multiple sclerosis.
Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation
TLDR
In conclusion, with the exception of those subjects who appeared to have no PBR binding, [(11)C]PBR28 is a promising ligand to quantify P BRs and localize inflammation associated with increased densities of PBRs.
...
1
2
3
4
5
...